Combination therapy with PEG-IFN and RBV for HCV infection often causes anemia, prompting RBV dose reduction/discontinuation. The aim of this study was to determine the optimal dose of erythropoietin (EPO) to increase Hb in anemic HCV-infected Japanese patients, and to assess whether EPO could maintain RBV dose and improve QOL. Nine patients who developed anemia were injected 12,000, 24,000 or 36,000 IU EPO subcutaneously once weekly for 12 weeks. The mean changes from baseline Hb levels at week 12 were +0.9 g/dL (12,000 IU), 1.1 g/dL (24,000 IU), and 1.8 g/dL (36,000 IU), respectively. RBV doses were maintained during EPO injection, and QOL scores of SF-36 and FACT-Anemia were improved significantly. EPO was well tolerated, and adverse events were not observed. EPO maintained RBV, and improved QOL and Hb in anemic patients. 24,000 to 36,000 IU epoetin beta once weekly appeared to be optimal dose for Japanese patients.
View full abstract